Europris aims at a dividend payout ratio of 50-60 per cent of the group’s net profit. Europris intends to provide shareholders with a competitive return on invested capital, taking into account the group’s risk profile. It plans to pay out surplus liquidity (funds not necessary for the group’s day-to-day operations) in the form of a dividend or by means of a capital reduction through distribution to the shareholders. The group considers whether the available liquidity should be used for new investment or repayment of debt instead of being paid out as dividend. Subject to the approval of the AGM, the aim is to pay dividend annually. Dividend payments are subject to certain legal restrictions pursuant to the Norwegian Public Limited Companies Act, and should also take account of the group’s capital requirements and financial position as well as general business conditions.
Dividend for year |
Dividend proposal |
Dividend (NOK) |
Date of approval |
Payment date |
2023 |
01.02.2024 |
3.25 |
30.04.2024 |
13.05.2024 |
2022 |
02.02.2023 |
3.754 |
20.04.2023 |
02.05.2023 |
2021 |
03.02.2022 |
4.003 |
21.04.2022 |
29.04.2022 |
2020 |
04.02.2021 |
2.702 |
05.05.2021 |
18.05.2021 |
2019 |
30.01.2020 |
1.95 |
29.04.2020 |
08.05.2020 |
2018 |
31.01.2019 |
1.85 |
23.05.2019 |
04.06.2019 |
2017 |
01.02.2018 |
1.70 |
23.05.2018 |
01.06.2018 |
2016 |
17.02.2017 |
2.001 |
23.05.2017 |
02.06.2017 |
2015 |
01.04.2016 |
1.40 |
13.05.2016 |
26.05.2016 |
1 Ordinary dividend of NOK 1.50 per share and an extraordinary anniversary dividend of NOK 0.50 per share
2 Ordinary dividend of NOK 2.20 per share and an additional dividend of NOK 0.50 per share to reflect the strong financial performance in an extraordinary year
3 Ordinary dividend of NOK 2.50 per share and an additional dividend of NOK 1.50 per share to reflect the strong financial performance
4 Ordinary dividend of NOK 2.75 per share and an additional dividend of NOK 1.00 per share to reflect the strong financial performance and solid financial position after a period still affected by Covid-19.